OpenAI’s CEO, Sam Altman, strengthens his partnership with Retro Biosciences. Their mutual mission? To add 10 more productive years to a well-lived human life. Based in San Francisco, this biotech startup is on pace to redefine what we consider a ‘healthy’ lifespan.
Already having backed the company’s full seed round to the tune of $180 million, Altman plays a significant role in the upcoming $1B Series A funding of Retro Biosciences, as reported by The Financial Times.
Emphasizing fast-paced innovation, Retro Biosciences set its sights on battling daunting diseases like Alzheimer’s. In fact, the company recently collaborated with OpenAI to develop a model that converts regular cells into stem cells. Retro Biosciences’ CEO, Joe Betts-LaCroix, sees the 2020s as the ideal time frame to unearth and introduce a groundbreaking drug.
Joining this revolutionary campaign are other billionaire-supported longevity projects like Altos Labs and Unity Biotechnology, backed by business luminaries like Jeff Bezos and Peter Thiel.
Original source: Read the full article on TechCrunch
